GC
RCKT icon

Guggenheim Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Guggenheim Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,985
Closed -$269K – 1929
2024
Q1 		$269K Buy
9,985
+1,605
+19% +$45.6K ﹤0.01% 1694
2023
Q4 		$251K Buy
+8,380
New +$185K ﹤0.01% 1736
2023
Q2 		– Sell
-11,757
Closed -$201K – 1927
2023
Q1 		$201K Buy
11,757
+1,087
+10% +$21.3K ﹤0.01% 1804
2022
Q4 		$209K Buy
+10,670
New +$196K ﹤0.01% 1793
2017
Q4 		– Sell
-2,610
Closed -$19K – 2792
2017
Q3 		$19K Buy
+2,610
New +$11.9K ﹤0.01% 2752

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Guggenheim Capital's RCKT Position: Q2 2024 in Review

Guggenheim Capital sold out of Rocket Pharmaceuticals (RCKT) in Q2 2024, closing a stake of 9,985 shares — an estimated $269K sold.

Guggenheim Capital first reported a position in RCKT in Q3 2017 and held it in 5 quarters. The position peaked at $269K in Q1 2024. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2024.

  • Guggenheim Capital reported no remaining Rocket Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Guggenheim Capital sold 9,985 Rocket Pharmaceuticals shares in Q2 2024, an estimated $269K.
  • Guggenheim Capital first reported a position in Rocket Pharmaceuticals in Q3 2017 and held it in 5 quarters.
  • Guggenheim Capital's Rocket Pharmaceuticals position peaked at $269K in Q1 2024.
  • 178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2024.

Based on Guggenheim Capital's 13F filing for Q2 2024, filed 14 Aug 2024.